DrugPatentWatch Database Preview
Pharmacyclics Inc Company Profile
What is the competitive landscape for PHARMACYCLICS INC, and when can generic versions of PHARMACYCLICS INC drugs launch?
There are twenty-four US patents protecting PHARMACYCLICS INC drugs.
There are one hundred and ninety-eight patent family members on PHARMACYCLICS INC drugs in thirty-eight countries and twenty-three supplementary protection certificates in eleven countries.
Summary for Pharmacyclics Inc
| International Patents: | 198 |
| US Patents: | 24 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 2 |
Drugs and US Patents for Pharmacyclics Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-001 | Feb 16, 2018 | RX | Yes | No | 8,754,090 | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-001 | Feb 16, 2018 | RX | Yes | No | 8,703,780 | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-001 | Feb 16, 2018 | RX | Yes | No | 7,514,444 | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-001 | Nov 13, 2013 | RX | Yes | Yes | 9,125,889 | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Non-Orange Book US Patents for Pharmacyclics Inc
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 9,409,911 | Inhibitors of bruton's tyrosine kinase | ➤ Try a Free Trial |
| 9,127,012 | Inhibitors of bruton's tyrosine kinase | ➤ Try a Free Trial |
| 8,236,812 | Inhibitors of bruton's tyrosine kinase | ➤ Try a Free Trial |
| 7,960,396 | Inhibitors of Bruton's tyrosine kinase | ➤ Try a Free Trial |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Pharmacyclics Inc Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Eurasian Patent Organization | 201000599 | ➤ Try a Free Trial |
| Japan | 2012105681 | ➤ Try a Free Trial |
| South Korea | 20100007864 | ➤ Try a Free Trial |
| South Korea | 20130027536 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Pharmacyclics Inc Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 3 5006-2015 | Slovakia | ➤ Try a Free Trial | PRODUCT NAME: IBRUTINIB; REGISTRATION NO/DATE: EU/1/14/945 20141023 |
| 2015017 | Lithuania | ➤ Try a Free Trial | PRODUCT NAME: IBRUTINIBUM; REGISTRATION NO/DATE: EU/1/14/945 20141021 |
| 2015000027 | Germany | ➤ Try a Free Trial | PRODUCT NAME: LBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/945 20141021 |
| 2016034 | Lithuania | ➤ Try a Free Trial | PRODUCT NAME: IBRUTINIBAS ARBA FARMACISKAI PRIIMTINA JO DRUSKA; REGISTRATION NO/DATE: EU/1/14/945 C(2016)3293 20160526 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.
